RxDoctor Payments Data

Marc Wasserman, MD

Neurology · Littleton, CONPI 1356340467

Payments from drug & device makers

$10,233in general payments, 2019–2025

Across 407 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$612
  • Lilly USA, LLC$511
  • UCB, Inc.$509
  • Amgen$485
  • Biohaven Pharmaceuticals, Inc.$434
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$1081%
  • Food & beverage$10,12299%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)87$2,012
Neurocrine Biosciences, Inc.11$612
Lilly USA, LLC24$511
UCB, Inc.23$509
Amgen15$485
Biohaven Pharmaceuticals, Inc.10$434
Biohaven Pharmaceutical Holding Company Ltd.7$411
SK Life Science, Inc.12$404
Eisai Inc.14$386
Lundbeck LLC7$362
Sanofi16$343
Medtronic13$271
Pfizer12$255
Teva Pharmaceuticals USA, Inc.19$217
TG Therapeutics, Inc.2$212
Novartis12$198
Tanabe Pharma America, Inc.7$194
EMD Serono, Inc.9$170
Otsuka America Pharmaceutical, Inc.7$154
MDD US Operations, LLC8$153
Penumbra, Inc.1$148
AstraZeneca(2 entities)2$142
Averitas Pharma Inc.5$131
Supernus Pharmaceuticals, Inc.7$110
Acorda Therapeutics, Inc4$108
Biogen5$104
Acadia Pharmaceuticals Inc4$80
Impel Pharmaceuticals Inc.3$73
Sunovion Pharmaceuticals Inc.6$70
Aquestive Therapeutics, Inc.4$66
Adamas Pharmaceuticals, Inc.3$65
Vanda Pharmaceuticals Inc.2$62
Livanova USA, Inc.3$56
Avanir Pharmaceuticals, Inc.3$52
Amneal Pharmaceuticals LLC3$48
Bridgebio Pharma, Inc.2$45
Ipsen Biopharmaceuticals, Inc3$42
Jazz Pharmaceuticals Inc.2$40
Vertical Pharmaceuticals, LLC2$40
Greenwich Biosciences, Inc.2$40
Akcea Therapeutics, Inc.2$38
Arbor Pharmaceuticals, Inc.2$37
Travere Therapeutics, Inc.5$35
GE HealthCare1$26
Alfasigma USA, Inc.1$24
Grifols USA, LLC1$23
Mallinckrodt Enterprises LLC1$22
CSL Behring1$22
Johnson & Johnson1$22
Neurelis, Inc.1$19
Portola Pharmaceuticals, LLC1$19
Merz North America, Inc.1$18
Currax Pharmaceuticals LLC1$16
Kyowa Kirin, Inc.1$16
GRT US Holding, Inc.1$16
Bausch Health US, LLC1$15
Azurity Pharmaceuticals, Inc.1$15
Saol Therapeutics Inc.1$12
Mallinckrodt Hospital Products Inc.1$12
Zyla Life Sciences, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,233 in reported general payments places this provider in the 65th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$99,342
Medicare patients
391
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate13$65,435
IngrezzaValbenazine Tosylate11$61,302
Aimovig AutoinjectorErenumab-Aooe42$35,810
Emgality PenGalcanezumab-Gnlm15$29,825
Nurtec OdtRimegepant Sulfate20$27,641
Memantine Hcl126$5,932
Donepezil Hcl239$2,693
Levetiracetam49$2,362
Lacosamide22$2,006
Memantine Hcl ErMemantine Hcl15$1,403
Duloxetine Hcl51$1,196
Gabapentin79$980
Lamotrigine39$975
Carbidopa-LevodopaCarbidopa/Levodopa52$955
Propranolol Hcl50$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$80$65,43513 claims
Neurocrine Biosciences, Inc.Ingrezza$612$61,30211 claims
PfizerNurtec Odt$255$27,64120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 334 neurology providers in Colorado.

Other neurology in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →